FDA Announces Potential Legal Path for CBD Products

— Written By Marne Coit and last updated by
en Español

El inglés es el idioma de control de esta página. En la medida en que haya algún conflicto entre la traducción al inglés y la traducción, el inglés prevalece.

Al hacer clic en el enlace de traducción se activa un servicio de traducción gratuito para convertir la página al español. Al igual que con cualquier traducción por Internet, la conversión no es sensible al contexto y puede que no traduzca el texto en su significado original. NC State Extension no garantiza la exactitud del texto traducido. Por favor, tenga en cuenta que algunas aplicaciones y/o servicios pueden no funcionar como se espera cuando se traducen.

English is the controlling language of this page. To the extent there is any conflict between the English text and the translation, English controls.

Clicking on the translation link activates a free translation service to convert the page to Spanish. As with any Internet translation, the conversion is not context-sensitive and may not translate the text to its original meaning. NC State Extension does not guarantee the accuracy of the translated text. Please note that some applications and/or services may not function as expected when translated.

Collapse ▲

4/3/2019 – The FDA released a statement on April 2, 2019, announcing steps it will take to create potential legal pathways for products made from hemp, including CBD. The agency recognizes the need to create regulations for products made from CBD. The products that the FDA regulates that would be impacted include human and animal food and drugs, cosmetics and dietary supplements.

The first step is a public hearing to be held on May 31, 2019, from 8 a.m.–6 p.m. in Silver Spring, MD. In particular, the agency is considering information about safety concerns related to CBD, including dosage, mode of delivery and how CBD interacts with medications.


In addition, the agency is creating an internal working group to consider whether there is a legal pathway for human food and dietary supplements that contain CBD to be marketed and sold.

The FDA also stated that it will issue warning letters to companies that are currently selling products with CBD that it considers to be illegal, including foods and dietary supplements that contain CBD and companies that make unsubstantiated health claims about products that contain CBD.

Read the FDA’s full statement.